Pharmacologic management of Alzheimer disease
| Autor: | Deborah Downey |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
N-Methylaspartate Pharmacological management MEDLINE Phenylcarbamates Rivastigmine Disease Pharmacotherapy Piperidines Alzheimer Disease Memantine medicine Humans Donepezil Intensive care medicine Nootropic Agents Endocrine and Autonomic Systems business.industry Galantamine Treatment options medicine.disease Medical–Surgical Nursing Indans Surgery Drug Therapy Combination Neurology (clinical) Cholinesterase Inhibitors Alzheimer's disease business medicine.drug |
| Zdroj: | The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses. 40(1) |
| ISSN: | 0888-0395 |
| Popis: | Although the diagnosis of AD can be devastating, treatment options exist that can slow the disease's progression and allow patients to continue performing ADLs, thereby improving the quality of life for both patient and caregiver. Research is ongoing, and it is estimated by the Alzheimer's Association that finding a treatment that could delay onset by only 5 years could reduce the number of individuals with AD by nearly 50% over the next 50 years (Alzheimer's Association, 2007). Although pharmacotherapy is not yet a cure, it does remain an important part of a total approach to caring for patients and families affected by AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|